Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2171-2175

  Sader, Helio S ^a,b   Fritsche, Thomas R ^a,d   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; ICLAPRIM; LEVOFLOXACIN; LINEZOLID; TETRACYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; EUROPE; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HOSPITALIZATION; HUMANS; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNITED STATES;

EID: 66149128050     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00129-09     Document Type: Article

References (21)

1. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard CLSI M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard CLSI M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Eisenstein, B. I. 2008. Treatment challenges in the management of complicated skin and soft-tissue infections. Clin. Microbiol. Infect. 14(Suppl. 2):17-25.
6. Ferone, R., S. R. Bushby, J. J. Burchall, W. D. Moore, and D. Smith. 1975. Identification of Harper-Cawston factor as thymidine phosphorylase and removal from media of substances interfering with susceptibility testing to sulfonamides and diaminopyrimidines. Antimicrob. Agents Chemother. 7:91-98.
7. Hawser, S., S. Lociuro, and K. Islam. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71:941-948. (Pubitemid 43306786)
8. Hawser, S., L. Weiss, M. Fischer, J. Jaeger, S. Greiveldinger, D. Gillessen, I. M. Kompis, and K. Islam. 2002. AR-100, a novel diaminophyrimidine compound: bactericidal activity and post-antibiotic effect on gram-positive pathogens. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA, 27 to 30 September 2002.
9. Hentschke, M., B. Saager, M. Horstkotte, S. Scherpe, M. Wolters, H. Kabisch, R. Grosse, P. Heisig, M. Aepfelbacher, and H. Rohde. 2008. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 36:85-87.
10. Jones, M. E., D. C. Draghi, P. K. Grover, S. Hawser, K. Islam, and F. Sahm. 2007. Bactericidal activity and post antibiotic effect of iclaprim (ICL) against Staphylococcus aureus (SA). Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2007.
11. Kohlhoff, S. A., and R. Sharma. 2007. Iclaprim. Expert Opin. Investig. Drugs 16:1441-1448.
12. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060.
13. Moody, J., and C. Knapp. 2004. Tests to assess bactericidal activity, p. 5.10.31-36. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. ASM Press, Washington, DC.
14. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antibacterial agents; approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Oefner, C., M. Bandera, A. Haldimann, H. Laue, H. Schulz, S. Mukhija, S. Parisi, L. Weiss, S. Lociuro, and G. E. Dale. 2009. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J. Antimicrob. Chemother. 63:687-698.
16. Peppard, W. J., and C. D. Schuenke. 2008. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr. Opin. Investig. Drugs 9:210-225.
17. Raghavan, M., and P. K. Linden. 2004. Newer treatment options for skin and soft tissue infections. Drugs 64:1621-1642. (Pubitemid 39128001)
18. Schneider, P., S. Hawser, and K. Islam. 2003. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13:4217-4221. (Pubitemid 37410316)
19. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
20. Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, and J. C. Wade. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406. (Pubitemid 41581713)
21. Then, R. L., H. H. Locher, and P. Angehrn. 2002. AR-100, a novel diaminopyrimidine compound: in vitro activity against gram-positive and gramnegative bacterial pathogens. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA, 27 to 30 September 2002.